

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,615	07/27/2006	Myung-Hwa Kim	HANOL-10659	6138
23535 7590 05/06/2008 MEDLEN & CARROLL, LLP			EXAMINER	
101 HOWARD STREET			SZNAIDMAN, MARCOS L	
SUITE 350 SAN FRANCI	SCO, CA 94105		ART UNIT	PAPER NUMBER
	,		1611	
			MAIL DATE	DELIVERY MODE
			05/06/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/562,615 KIM ET AL. Examiner Art Unit MARCOS SZNAIDMAN 1611 The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Reply

	MARCOS SZIVAIDIVAN	1011	
<i>The</i> Period for Rep	MAILING DATE of this communication appears on the cover sheet with the ly	correspondence ad	dress
WHICHEVE - Extensions of after SIX (6) N - If NO period fi - Failure to repl Any reply received.	NED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH- FOR IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATIO time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a rejey be to for reply is specified above, the maximum statutory period will apply and will expire SIX (8) MONTHS from ywithin the set or cateford period for reply with by statute, cause the application to become ARANDONS ieved by the Office later than three months after the mailing date of this communication, even if timely file term adjustmens. See 37 CFR 1.70(de).	N. mely filed in the mailing date of this of ED (35 U.S.C. § 133).	,
Status			
1)⊠ Resp	onsive to communication(s) filed on 27 July 2006.		
7—	action is FINAL. 2b) This action is non-final.		
	this application is in condition for allowance except for formal matters, pnd in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 4		merits is
Disposition of	Claims		
4)⊠ Claim	(s) <u>1-6</u> is/are pending in the application.		
4a) Of	the above claim(s) is/are withdrawn from consideration.		
	(s) is/are allowed.		
	(s) is/are rejected.		
	(s) is/are objected to.		
8)⊠ Claim	(s) <u>1-6</u> are subject to restriction and/or election requirement.		
Application Pa	pers		
9)∐ The sp	pecification is objected to by the Examiner.		
10) <u></u> The di	rawing(s) filed on is/are: a) accepted or b) objected to by the	Examiner.	
Applic	ant may not request that any objection to the drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).	
Repla	cement drawing sheet(s) including the correction is required if the drawing(s) is ob-	jected to. See 37 CF	FR 1.121(d)
11) ☐ The oa	ath or declaration is objected to by the Examiner. Note the attached Office	Action or form PT	O-152.
Priority under	35 U.S.C. § 119		
	wledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a b) ☐ Some * c) ☐ None of:)-(d) or (f).	
1.	Certified copies of the priority documents have been received.		
2.	Certified copies of the priority documents have been received in Applicat	ion No	
3.□	Copies of the certified copies of the priority documents have been receive	ed in this National	Stage
	application from the International Bureau (PCT Rule 17.2(a)).		
* See the	e attached detailed Office action for a list of the certified copies not receive	∍d.	
Attachment(s)			
\	ferences Cited (PTO-892) 4) Interview Summary	(PTO-413)	

Attachment(s)		
1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/S5/08) Paper No(s)/Mail Date	4) Interview Summary (PTO-413) Paper No(s)Mail Date. 5) Notice of Informal Patent Application 6) Other:	
rapel No(s)/Wall Date	0)	

Art Unit: 1615

DETAILED ACTION

Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3 and 5-6, drawn to a tricyclic derivative represented by formula I (see claim 1).

Group II, claim(s) 4, drawn to a method for preparing tricyclic derivatives.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the common technical feature in all groups is a tricyclic derivative of general structure represented by Formula I (see claim 1). This element cannot be a special technical feature under PCT rule 13.2 because the element is shown in the prior art. For example: Guan et. al. (J. Med. Chem. (1998) 41:1956-1961), describe similar compounds (see compounds 16-26 on Scheme 1, page 1958).

Elections

Art Unit: 1615

Election for Groups I and II

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows: compounds of formula 1 listed in claim 1. Applicant is required to elect a single disclosed species. Specifically, applicant is required to define each of R1, R2, R3and R4 groups with a particular species (a species definition like methyl, not a genus definition like alkyl). Electing a compound that is not specifically disclosed as filed may be considered new matter.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: 1-6.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or

Art Unit: 1615

corresponding special technical features for the following reasons: these structures are known in the prior art (see Guan et. al. (J. Med. Chem. (1998) 41:1956-1961), see compounds 16-26 on Scheme 1, page 1958).

Rejoinder Notice

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result

Art Unit: 1615

in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Inventorship Notice

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached on Monday through Thursday 8 AM to 6 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael P. Woodward can be reached on 571 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/562,615 Page 6

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/MARCOS SZNAIDMAN/ Examiner, Art Unit 1611 April 22, 2008 /MP WOODWARD/ Supervisory Patent Examiner, Art Unit 1615